BiotechTube
DISITBiotech

DISITBiotech

Barcelona, Spain· Est.
disitbiotech.com
Is this your company? Claim your profile to update info and connect with investors.
Claim profile

Private Company

Funding information not available

Overview

DISIT Biotech, founded in 2019 and based in Barcelona, is a preclinical-stage biotech developing peptide-based inhibitors of TGF-β to treat complications from cancer radiotherapy, such as fibrosis. The company has garnered recognition through awards and grants, indicating validation of its innovative approach. It operates as a private, pre-revenue entity, advancing its lead asset through research and preclinical development with a focus on translating scientific discovery into clinical solutions for global health.

OncologyFibrotic Diseases

Technology Platform

Peptide-based inhibitors of the Transforming Growth Factor Beta (TGF-β) pathway, derived from the TGF-β type III receptor.

Opportunities

Large unmet need in radiation-induced fibrosis with no approved therapies, creating a clear market entry point.
The TGF-β inhibition platform has potential for expansion into other fibrotic diseases and immuno-oncology combinations, offering significant pipeline expansion opportunities.

Risk Factors

High preclinical-to-clinical translational risk for its lead peptide asset.
As a pre-revenue company, it faces significant funding risk to advance into costly clinical trials.
Competition from other entities targeting the TGF-β pathway in broader indications poses a long-term threat.

Competitive Landscape

The competitive landscape includes companies developing anti-fibrotic therapies (e.g., for IPF, NASH) and those targeting the TGF-β pathway in oncology (e.g., bifunctional antibodies, kinase inhibitors). However, DISIT's specific focus on peptide-based inhibition for radiotherapy complications may carve out a specialized niche with less direct competition initially.

More companies in Spain →